Australia's OncoSil Medical soars on regulatory nod for cancer device
20/05/2026 01:27
** Shares of Australia's OncoSil Medical OSL.AX rise as much as 46.2% to A$0.570, logging their best intraday pct gain since June 2, 2025 ** Stock hits its highest level since March 16 ** Medical device firm receives approval from Australian Therapeutic Goods Administration (TGA) for OncoSil device for treatment of pancreatic cancer in Australia ** Says device targets tumours directly within pancreas ** TGA is the Australian government's regulatory agency for medical products ** Stock down 45% this year, including the day's move (Reporting by Rajasik Mukherjee in Bengaluru) ((Rajasik.Mukherjee@thomsonreuters.com))
Recent news on Oncosil Medical
See all newsAustralia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone
Brief: Oncosil Medical Says FDA Grants Hde Approval For Oncosil Device For Distal Cholangiocarcinoma
Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
Brief: Oncosil Medical Receives Saudi FDA Approval
Brief: Oncosil Medical Files For FDA Approval